New Weapon in BioDefense Research: NanoLogix Kit Speeds Rapid Diagnostics of Anthrax and Bubonic Plague
HUBBARD, Ohio, April 13, 2009 /PRNewswire-FirstCall via COMTEX/ -- NanoLogix, Inc. (OTC: NNLX) a biotechnology company, is pleased to provide the following information:
An independent study has found that NanoLogix's BNPâ„?Ultra-Fast Identification Technology allows the viewing of anthrax cultures four times faster than conventional methods.
The study, by one of the foremost bio-defense and biomedical research centers in the U.S., appears in the current online issue of Letters in Applied Microbiology. The authors found that NanoLogix's BNP(TM) technology displayed colonies of anthrax in six hours, as contrasted with the fastest traditional methods, which typically take 24 hours.
The study also found that the NanoLogix BNPâ„?technology allowed viewing of cultures of bubonic plague, known historically as the "Black Death", twice as fast as traditional Petri plate methods.
The study, by an independent lab under strict protocols, confirms the value of NanoLogix's breakthrough technology when time is a crucial factor. The BNPâ„?method has proven to be much faster than any other method in the broad field of Petri dish testing.
The authors of the study concluded that the NanoLogix technology could lead to a more rapid assessment of surface sampling and decontamination measures, and could aid in the evaluation of medical countermeasures and treatments.
The study appears in the current online issue of Letters in Applied Microbiology.
Links to study:
NanoLogix's BNPâ„?Ultra Fast Identification Technology has applications for fields outside the bio-defense arena as well, including epidemiology, hospital diagnosis, veterinary medicine and food safety.
NanoLogix CEO Bret Barnhizer stated "We are elated with the results of the study and look forward to increased public awareness of the broad capabilities of the BNPâ„?Ultra-Fast kits. We believe that the BNPâ„?sandwiched-membrane is the next evolutionary step in Petri technology and will be the kit of choice whenever faster test results are essential."
The bacteria responsible for Anthrax and Bubonic plague are category A select agents, due to their capacity to cause illness and death. These micro-organisms are a preferred bio-weapon of terrorists. As these agents are highly dangerous all testing was done in a BioSafety Level 3 laboratory (BSL-3). This is protocol required with category A select agents, which can cause serious or potentially lethal disease after inhalation.
The BNPâ„?technology provided similar colony counts for anthrax in 6 hours as obtained with the traditional Petri method in 24 hours. For Bubonic plague, the BNPâ„?colony count in 24 hours was also similar to what the traditional methodology achieved in 48 hours.
In 2001, letters containing anthrax spores were mailed to several news media offices and to the offices of two U.S. Senators, killing five people and infecting 17 others, throwing the nation into a near panic. During the first crucial hours of infection or threat, rapid confirmation of the presence of biological agents can mean the difference between life and death, between a widespread public panic and a smooth containment strategy.In the event of future attacks such as occurred in 2001, the hope is that the BNP'sâ„?ability to assist in determining the threat posed by biologic agents will contribute to a more rapid diagnosis and response.
About NanoLogix, Inc.
NanoLogix is a biotechnology company focused primarily on medical diagnostics. Its products offer accelerated detection and identification of microorganisms present in infectious and non-infectious human diseases, such as tuberculosis, NTM, pneumonia, HIV/AIDS, cancer, cystic fibrosis, anthrax, and plague. In addition to medical and homeland security applications, NanoLogix technology is applicable in pharmaceutical, industrial, veterinary and environmental testing.
Patents granted to NanoLogix can be used in the areas of applied microbiology, soil microbiology and bioremediation, microbial physiology, molecular biology, pharmacology, pharmaco-kinetics, antibiotic sensitivity, stem-cell research, and bioreactor-based hydrogen generation.
More information on NanoLogix is available at www.nanologixinc.com.
This press release contains statements, which may constitute "forward- looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of NanoLogix, Inc., and members of its management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. The Company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.
Copyright 2010 NanoLogix, Inc All Rights Reserved